In Q3 FY2026 (ended January 23, 2026), Medtronic reported revenue of $9.017 billion, up 8.7% year-over-year. Net income was $1.143 billion, down 11.7% from the prior year. Operating income decreased 11.1% to $1.464 billion, and diluted EPS fell 11.9% to $0.89.
•Revenue grew 8.7% YoY to $9.017 billion.
•Net income declined 11.7% YoY to $1.143 billion.
•Operating income fell 11.1% YoY to $1.464 billion.
•Diluted EPS decreased 11.9% YoY to $0.89.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Medtronic develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients globally. Its business is organized into three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio.
The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices. Its portfolio also includes cardiac ablation products, insertable cardiac monitor systems, TYRX products, and remote monitoring and patient-centered software
Aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products.
The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products
Nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists Ear, nose, and throat specialists, and energy surgical instruments.
The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Founded in 1949, Medtronic is headquartered in Galway, Ireland.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients globally. Its business is organized into three segments: the Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio includes implantable cardiac pacemakers, cardioverter defibrillators, cardiac resynchronization therapy devices, cardiac ablation products, insertable cardiac monitors, TYRX products, remote monitoring software, aortic and surgical valves, endovascular stent grafts, transcatheter pulmonary valves, left atrial appendage exclusion systems, ECMO systems, and percutaneous coronary intervention products. The Neuroscience Portfolio offers spinal cord stimulation and brain modulation systems, implantable drug infusion systems, nerve ablation systems (Accurian), and products for spinal, neurological, pain management, urological, and ENT procedures. The Medical Surgical Portfolio provides surgical stapling devices and vessel sealing instruments.
Where is Medtronic (MDT) listed and in which currency?
Medtronic plc is listed on the New York Stock Exchange (NYSE) under the ticker symbol MDT. Its stock trades in US Dollars (USD). As a company incorporated in Ireland with a primary listing on a US exchange, Medtronic reports its financial results in USD, making it accessible to global investors through the NYSE.
What sector and industry does Medtronic (MDT) operate in?
Medtronic operates in the Healthcare sector, specifically within the Medical Devices industry. This industry focuses on developing and manufacturing equipment, instruments, and implants used to diagnose, monitor, and treat medical conditions. Medtronic is one of the largest medical device companies globally, with a broad portfolio spanning cardiovascular, neurological, and surgical applications.
Where is Medtronic (MDT) headquartered and what markets does it serve?
Medtronic plc is headquartered in Ireland, though it has a significant operational presence in the United States and other countries. The company serves healthcare systems, physicians, clinicians, and patients globally. Its products are used in hospitals, clinics, and other healthcare settings worldwide, with a focus on delivering device-based medical therapies across cardiovascular, neuroscience, and medical surgical specialties.
How does Medtronic (MDT) make money?
Medtronic generates revenue by selling medical devices and therapies across three main segments. The Cardiovascular Portfolio contributes through products like pacemakers, defibrillators, heart valves, stents, and ablation systems. The Neuroscience Portfolio earns from spinal implants, neuromodulation devices, drug infusion systems, and surgical instruments for neurosurgery and pain management. The Medical Surgical Portfolio includes stapling and vessel sealing devices used in general surgery. The company also offers remote monitoring software and services, which support recurring revenue streams. Medtronic's diverse product range allows it to serve multiple medical specialties and generate income from both device sales and associated services.